Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 71.3%

Neg 0% Neu 0% Pos 71.3%

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.